WELCOME TO The PHARMACEUTICAL REPORT
Solid Dose Trends 2019
May 29, 2019
I'm For Real
Enter your details once to access all our information and resources
Avella's mission is to optimize patient health through a relentless devotion to clinical excellence. This philosophy is the primary reason we’ve become a leader in the specialty pharmacy industry.
whitePaper | January 3, 2022
There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs
whitePaper | January 1, 2020
With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide.
Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.
whitePaper | February 5, 2022
Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains
ensure that the right amount of medicine, with acceptable quality, will reach the customers in need
whitePaper | November 25, 2019
It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.
whitePaper | February 24, 2022
The COVID-19 pandemic and resulting economic dislocation revealed long-standing vulnerabilities in our
supply chains. The pandemic’s drastic impacts on demand patterns for a range of medical products including
essential medicines wreaked havoc on the U.S. healthcare system.
whitePaper | April 1, 2021
Every year, the U.S. pharmaceutical industry develops
a variety of new drugs that provide valuable medical
benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and
the federal government. Policymakers have considered
policies that would lower drug prices and reduce federal
drug expenditures. Such policies would probably reduce
the industry’s incentive to develop new drugs.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE